Experimental HCV Drugs
Experimental HCV Drugs
ICAAC 2014: AbbVie 3D Combination Works Well for People with HIV/HCV Coinfection
- Details
- Category: Experimental HCV Drugs
- Published on Sunday, 07 September 2014 00:00
- Written by Liz Highleyman
An all-oral regimen of 3 direct-acting antivirals plus ribavirin taken for 12 weeks led to sustained virological response in 94% of HIV positive people with mostly genotype 1a hepatitis C coinfection in the TURQUOISE-I study, according to data presented at the 54th Interscience Conference on Antimicrobial Agents and Chemotherapy this week in Washington, DC.
European Regulators Approve Daclatasvir for Hepatitis C
- Details
- Category: Experimental HCV Drugs
- Published on Thursday, 28 August 2014 00:00
- Written by HIVandHepatitis.com
The European Medicines Agency, which handles regulatory approval for 28 countries of the European Union, this week approved Bristol-Myers Squibb's hepatitis C virus NS5A inhibitor daclatasvir (Daklinza) for use in combination therapy for HCV genotypes 1, 2, 3, and 4.
Studies Show High Cure Rates for Interferon-free Hepatitis C Treatment
- Details
- Category: Approved HCV Drugs
- Published on Tuesday, 12 August 2014 00:00
- Written by HIVandHepatitis.com
An all-oral combination of daclatasvir (Daklinza) plus asunaprevir led to sustained virological response (SVR) in 82%-90% of treatment-naive and previously treated people with hepatitis C virus genotype 1b, while a regimen of sofosbuvir (Sovaldi) plus simeprevir (Olysio) cured 92%-94% of hepatitis C patients with or without cirrhosis, according to findings from a pair of clinical trials reported in the July 28 advance online edition of The Lancet.
Achillion HCV NS5A Inhibitor + Sofosbuvir Shows High Early Cure Rate
- Details
- Category: Experimental HCV Drugs
- Published on Thursday, 28 August 2014 00:00
- Written by Achillion
An interferon-free dual combination of Achillion's hepatitis C virus NS5A inhibitor ACH-3012 plus Gilead Science's HCV polymerase inhibitor sofosbuvir (Sovaldi) taken for 8 weeks led to sustained virological response at 4 weeks post-treatment for people with HCV genotype 1 in a Phase 2 study, according to a company announcement.
AIDS 2014: AbbVie Hepatitis C Treatment Works Well for People on Methadone or Buprenorphine
- Details
- Category: Experimental HCV Drugs
- Published on Thursday, 24 July 2014 00:00
- Written by Liz Highleyman
People with chronic hepatitis C who are using methadone or buprenorphine to manage opiate addiction can be safely and effectively treated with AbbVie's 3D all-oral direct-acting antiviral regimen plus ribavirin, resulting in a 97% cure rate, according to a report this week at the 20thInternational AIDS Conference in Melbourne.People with chronic hepatitis C who are using methadone or buprenorphine to manage opiate addiction can be safely and effectively treated with AbbVie's 3D all-oral direct-acting antiviral regimen plus ribavirin, resulting in a 97% cure rate, according to a report this week at the 20thInternational AIDS Conference in Melbourne.
Web Design and Development by